Effect of Tarantula cubensis alcohol extract and Capecitabin combine in Colorectal Cancer rats

• Rahmi Canbar Necmettin Erbakan University, Veterinary Medicine, Department of Pharmacology and Toxicology. Ereğli, Konya, Turkey
• Ozgur Ozdemir Selcuk University, Faculty of Veterinary Medicine, Department of Pathology. Selcuklu, Konya, Turkey
• Ahmet Levent Bas Selcuk University, Veterinary Medicine, Department of Pharmacology and Toxicology. Selcuklu, Konya, Turkey

DOI: https://doi.org/10.52973/rcfcv-e33254

Keywords: Azoxymethane, Capecitabine, colorectal cancer, TCAE

Abstract

Colon cancer (CRC) is one of the most common types of cancer in the world. In this study, the effects of Tarantula cubensis alcoholic extract (TCAE) and the Capecitabine in CRC were investigated. Wistar albino rats were divided into eight groups with 12 animals in each group: untreated healthy and CRC groups, healthy and CRC groups treated with TCAE or Capecitabine, and healthy and CRC groups treated with both TCAE and Capecitabine. Azoxymethane was used in all CRC groups. TCAE and Capecitabine were administered to the relevant groups starting in the 15th week. All rats were euthanized after 18 weeks, and tissue samples were collected. The mRNA levels of Bcl–2, Bax, and Cas–3 in the harvested tissues were determined using real–time PCR and histopathologically abnormal crypt foci (ACF) scores were determined. It was found that TCAE modulated the decreased Bax/Bcl–2 expression rate in the CC group, but had the opposite effect in healthy animals, which was significantly reduced compared to the healthy groups (P<0.05). In addition, this rate was significantly lower in Capecitabine administered groups compared to other groups, and a paradoxical effect was observed (P<0.05). No significant change was observed in Cas–3 expression levels in all groups (P>0.05). Importantly, single and combined use of TCAE and Capecitabine in rats with CRC significantly reduced ACF scores (P<0.05). It can be stated that TCAE can specifically modulate the decreased Bax/Bcl–2 ratio in animals with cancer, and the therapeutic efficacy of Capecitabine is achieved at a dose of 40 mg·kg^-1.

References

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Piñeros M, Znaor, A, Bray, F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Internat. J. Cancer. 2019; 144(8):1941–53.

Arteaga TA, McKnight J, Bergman PJ. A review of 18 cases of feline colonic adenocarcinoma treated with subtotal colectomies and adjuvant carboplatin. J. the Amer. Anim. Hospital Asso. 2012; 48(6):399–404.

Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. New England J. Med. 2009; 361(25):2449–60.

Mármol I, Sanchez de Diego C, Pradilla–Dieste A, Cerrada E, Rodriguez–Yoldi M. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Internat. J. Molecular Sci. 2017; 18(1):197.

Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, Zeng S. Possible pathways of Capecitabine–induced hand–foot syndrome. Chem. Res. Toxicol. 2016; 29(10):1591–601.

Midgley R, Kerr DJ. Capecitabine: have we got the dose right? Nature Rev. Clin. Oncol. 2009; 6(1):17.

Hirsch BR, Zafar SY. Capecitabine in the management of colorectal cancer. Cancer Manag. Res. 2011; 3:79–89.

Shindoh H, Nakano K, Yoshida T, Ishigai M. Comparison of in vitro metabolic conversion of Capecitabine to 5–FU in rats, mice, monkeys and humans–toxicological implications. J. Toxicol. Sci. 2011; 36(4):411–22.

Sakai S, Kobuchi S, Ito Y, Sakaeda T. Assessment of pharmacokinetic variations of Capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model. Cancer Chemotherap. Pharmacol. 2020; 85(5):869–80.

Walko CM, Lindley C. Capecitabine: a review. Clin. Therap. 2005; 27(1):23–44.

Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B. Preferential activation of Capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemotherap. Pharmacol. 2000; 45(4):291–7.

Richardson–Boedler C. The brown spider Loxosceles laeta: source of the remedy Tarentula cubensis? Homeopathy. 2002; 91(03):166–70.

Ghasemi–Dizgah A, Nami B, Amirmozafari N. Tarantula cubensis venom (Theranekron®) selectively destroys human cancer cells via activating caspase–3–mediated apoptosis. Acta Med. Intern. 2017; 4(1):74.

Gultekin N, Vural M. The effect of Tarantula cubensis extract applied in pre and post–operative period of canine mammary tumors. J. Istanbul Vet. Sci. 2007; 2(1):13–23.

Gultiken N, Guvenc T, Kaya D, Agaoglu AR, Ay SS, Kucukaslan I, Emre B, Findik M, Schäfer–Somi S, Aslan S. Tarantula cubensis extract alters the degree of apoptosis and mitosis in canine mammary adenocarcinomas. J. Vet. Sci. 2015; 16(2):213–9.

Icen H, Sekin S, Simsek A, Kochan A, Tunik S. The efficacy of Tarantula cubensis extract (Theranekron) in treatment of canine oral papillomatosis. Asian J. Anim. Vet. Adv. 2011; 6:744–9.

Karayannopoulou M, Lafioniatis S. Recent advances on canine mammary cancer chemotherapy: A review of studies from 2000 to date. Breast Cancer Res. 2016; 29(32):43.

Er A, Ozdemir O, Coskun D, Dik B, Bahcivan E, Faki HE, Yazar E. Effects of Tarantula cubensis alcoholic extract and Nerium oleander distillate on experimentally induced colon cancer. Develop. 2019; 45:47.

Adams JM, Cory S. The BCL–2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Different. 2018; 25(1):27.

Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA, Stellato TA. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res. 1991; 51(5):1564–7.

Bird RP, Good CK. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol. Lett. . 2000; 112:395–402.

Tan BL, Esa NM, Rahman HS, Hamzah H, Karim R. . Brewers’ rice induces apoptosis in azoxymethane–induced colon carcinogenesis in rats via suppression of cell proliferation and the Wnt signaling pathway. BMC Complem. Alternat. Med. 2014; 14(1):304.

Özdemir Ö, Akçakavak G, Tuzcu M. Effect of Tarantula cubensis alcoholic extract and Nerium oleander distillate on cell proliferation markers in colon carcinogenesis. Rev. Cientif. FCV–LUZ. 2022; 32:e–31250. doi: https://doi.org/kdc7

Kristiansen E. The role of aberrant crypt foci induced by the two heterocyclic amines 2–amino–3–methyl–imidazo [4, 5–f] quinoline (IQ) and 2–amino–1–methyl–6–phenyl–imidazo [4, 5–b] pyridine (PhIP) in the development of colon cancer in mice. Cancer Lett. 1996; 110(1–2):187–92.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real–time quantitative PCR and the 2− ΔΔCT method. Methods. 2001; 25(4):402–8.

Sakai S, Kobuchi S, Ito Y, Sakaeda T. A Physiologically Based Pharmacokinetic–Pharmacodynamic Model for Capecitabine in Colorectal Cancer Rats: Simulation of Antitumor Efficacy at Various Administration Schedules. Europ. J. Drug Metabol. Pharmacokin. 2021; 46(2):301–15.

Dudhipala N, Puchchakayala G. Capecitabine lipid nanoparticles for anti–colon cancer activity in 1, 2–dimethylhydrazine–induced colon cancer: preparation, cytotoxic, pharmacokinetic, and pathological evaluation. Drug Develop. Industr. Pharm. 2018; 44(10):1572–82.

Refaat B, El–Shemi AG, Kensara OA, Mohamed AM, Idris S, Ahmad J, Khojah A. Vitamin D3 enhances the tumouricidal effects of 5–Fluorouracil through multipathway mechanisms in azoxymethane rat model of colon cancer. J. Experim. Clin. Cancer Res. 2015; 34(1):1–15.

Abd AH, Hussein AG, Mahmood AS. Efficacy of intraperitoneal administration of metformin and 5–fluoruracil in prevention of induced colorectal aberrant crypt foci in mice. Intern. J. Pharm. Pharmaceut. Sci. 2014; 6:305–8.

Chen S, Peng H, Rowat A, Gao F, Zhang Z, Wang P, Zhang W, Wang, X, Qu L. The effect of concentration and duration of normobaric oxygen in reducing caspase–3 and–9 expression in a rat–model of focal cerebral ischaemia. Brain Res. 2015; 1618:205–11.

Benadiba M, Dos Santos RRP, Silva Dde O, Colquhoun A. Inhibition of C6 rat glioma proliferation by [Ru2Cl (Ibp) 4] depends on changes in p21, p27, Bax/Bcl2 ratio and mitochondrial membrane potential. J. Inorganic Biochem. 2010; 104(9):928–35.

Novak M, Žegura B, Baebler Š, Štern A, Rotter A, Stare K, Filipic M. Influence of selected anti–cancer drugs on the induction of DNA double–strand breaks and changes in gene expression in human hepatoma HepG2 cells. Environm. Sci. Pollut. Res. 2016; 23(15):14751–61.

Adeyemo D, Imtiaz F, Toffa S, Lowdell M, Wickremasinghe R, Winslet M. Antioxidants enhance the susceptibility of colon carcinoma cells to 5–fluorouracil by augmenting the induction of the bax protein. Cancer Lett. 2001; 164(1):77–84.

Wang W, Guo W, Li L, Fu Z, Liu W, Gao J, Shu Y, Xu Q, Sun Y, Gu Y. Andrographolide reversed 5–FU resistance in human colorectal cancer by elevating BAX expression. Biochem. Pharmacol. 2016; 121:8–17.

Meng X, Fu R. miR–206 regulates 5–FU resistance by targeting Bcl–2 in colon cancer cells. OncoTargets Therapy. 2018; 11:1757.

Li J, Hou N, Faried A, Tsutsumi S, Kuwano H. Inhibition of autophagy augments 5–fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Europ. J. Cancer. 2010; 46(10):1900–9.

Er A, Corum O, Corum D, Hitit M, Donmez H, Guzeloglu A. Alcoholic extract of Tarantula cubensis induces apoptosis in MCF–7 cell line. Biomed. Res. 2017; 28(8):3660–3665

Yenigun VB, Azzawri AA, Acar MS, Kaplan MB, Ucar VB, Tastekin D, Acar H. Alcoholic extract of Tarantula cubensis (Theranekron®) induce autophagy on gastric cancer cells. Experim. Biomed. Res. 2021; 4(2):89–98.

Akcakavak G, Ozdemır O. Effect of Tarantula cubensis alcoholic extract on tumour pathways in azoxymethane–induced colorectal cancer in rats. Acta Vet. Brno. 2023; 92(1):79–88.

ilhan S. Can a Veterinary Drug be Repurposed for Human Cancers?: Cytotoxic Effect of Tarantula cubensis Venom on Human Cancer Cells. J. Instit. Sci. Technol. 2021; 11(3):1763–9.

Dik B, Coskun D, Er A. Protective Effect of Nerium oleander Distillate and Tarantula cubensis Alcoholic Extract on Cancer Biomarkers in Colon and Liver Tissues of Rats with Experimental Colon Cancer. Anti–Cancer Agents Med. Chem. 2022; 22(10):1962–9.

Lewandowska U, Szewczyk K, Owczarek K, Hrabec Z, Podsedek A, Koziołkiewicz M, Hrabec E. Flavanols from evening primrose (Oenothera paradoxa) defatted seeds inhibit prostate cells invasiveness and cause changes in Bcl–2/Bax mRNA ratio. J. Agricult. Food Chem. 2013; 61(12):2987–98.

Haydé V–C, Ramón G–G, Lorenzo G–O, Dave OB, Rosalía R–C, Paul W, Guadalupe L–P. Non–digestible fraction of beans (Phaseolus vulgaris L.) modulates signalling pathway genes at an early stage of colon cancer in Sprague–Dawley rats. British J. Nutr. 2012; 108(S1):S145–S54.

Kuugbee ED, Shang X, Gamallat Y, Bamba D, Awadasseid A, Suliman MA, Zang S, Ma Y, Chiwala G, Xin Y. Structural change in microbiota by a probiotic cocktail enhances the gut barrier and reduces cancer via TLR2 signaling in a rat model of colon cancer. Digest. Dis. Sci. 2016; 61(10):2908–20.

Dik B, Sonmez G, Faki HE, Bahcivan E. Sulfasalazine treatment can cause a positive effect on LPS–induced endotoxic rats. Experim. Anim. 2018; 67(4):403–12.

Li P, Jiang H, Wu H, Wu D, Li H, Yu J, Lai J. AH6809 decreases production of inflammatory mediators by PGE2–EP2–cAMP signaling pathway in an experimentally induced pure cerebral concussion in rats. Brain Res. 2018; 1698:11–28.